phmacao legit
The Reform UK leader pushed back against reports suggesting that legal action would be the next step, saying he would make a decision in the next couple of days about his response if there is no apology for the “crazy conspiracy theory”. Mr Farage also said the party has “opened up our systems” to media outlets, including The Daily Telegraph and The Financial Times, in the interests of “full transparency to verify that our numbers are correct”. His remarks came after Conservative Party leader Kemi Badenoch accused Mr Farage of “fakery” in response to Reform claiming they had surpassed the Tories in signed-up members. Mrs Badenoch said Reform’s counter was “coded to tick up automatically”. A digital counter on the Reform website showed a membership tally before lunchtime on Boxing Day ticking past the 131,680 figure declared by the Conservative Party during its leadership election earlier this year. Mr Farage, on whether he was threatening legal action or not, told the PA news agency: “I haven’t threatened anything. I’ve just said that unless I get an apology, I will take some action. “I haven’t said whether it’s legal or anything.” He added: “All I’ve said is I want an apology. If I don’t get an apology, I will take action. “I will decide in the next couple of days what that is. So I’ve not specified what it is.” Mr Farage, on the move to make membership data available to media organisations, said: “We feel our arguments are fully validated. “She (Mrs Badenoch) has put out this crazy conspiracy theory and she needs to apologise.” The accusations of fraud and dishonesty made against me yesterday were disgraceful. Today we opened up our systems to The Telegraph, Spectator, Sky News & FT in the interests of full transparency to verify that our data is correct. I am now demanding @KemiBadenoch apologises. — Nigel Farage MP (@Nigel_Farage) December 27, 2024 On why Mrs Badenoch had reacted as she did, Mr Farage said: “I would imagine she was at home without anybody advising her and was just angry.” Mr Farage, in a statement issued on social media site X, also said: “The accusations of fraud and dishonesty made against me yesterday were disgraceful. “Today we opened up our systems to The Telegraph, Spectator, Sky News and FT in the interests of full transparency to verify that our data is correct. “I am now demanding Kemi Badenoch apologises.” A Conservative Party source claimed Mr Farage was “rattled” that his Boxing Day “publicity stunt is facing serious questions”. They added: “Like most normal people around the UK, Kemi is enjoying Christmas with her family and looking forward to taking on the challenges of renewing the Conservative Party in the New Year.” Mrs Badenoch, in a series of messages posted on X on Thursday, said: “Farage doesn’t understand the digital age. This kind of fakery gets found out pretty quickly, although not before many are fooled.” There were 131,680 Conservative members eligible to vote during the party’s leadership election to replace Rishi Sunak in the autumn. Mrs Badenoch claimed in her thread that “the Conservative Party has gained thousands of new members since the leadership election”. Elsewhere, Mr Farage described Elon Musk as a “bloody hero” and said he believes the US billionaire can help attract younger voters to Reform. Tech entrepreneur Mr Musk met Mr Farage earlier this month at Donald Trump’s Mar-a-Lago resort in Florida, amid rumours of a possible donation to either Mr Farage or Reform. Mr Farage told The Daily Telegraph newspaper: “The shades, the bomber jacket, the whole vibe. Elon makes us cool – Elon is a huge help to us with the young generation, and that will be the case going on and, frankly, that’s only just starting. “Reform only wins the next election if it gets the youth vote. The youth vote is the key. Of course, you need voters of all ages, but if you get a wave of youth enthusiasm you can change everything. “And I think we’re beginning to get into that zone – we were anyway, but Elon makes the whole task much, much easier. And the idea that politics can be cool, politics can be fun, politics can be real – Elon helps us with that mission enormously.”
Maharashtra Election Results 2024: 'Negative Politics, Parivarvaad Defeated,' Says PM Modi After Mahayuti's Landslide Victory; (VIDEO)
Mountain lion spotted in Oro ValleyDow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The stock market rally had a strong week, though Google-parent ( ) and some megacaps saw muted Nasdaq gains late in the week. One of those tech titans, ( ), wavered after earnings, ending the week flat but still in a buy zone. However, recent IPO ( ), a relatively small company, is now the clear leader in AI chip stocks. It was a strong week for leading stocks, with many flying into and often out of buy zones, including ALAB stock. ( ), ( ), ( ) and ( ) are all in traditional buy zones. ( ) and ( ) also are in buy zones after Friday breakouts. But both report on Tuesday. So do ( ), ( ), ( ) and ( ). CrowdStrike is extended from a buy point. ANF stock is near a trendline entry. Workday is working on a handle buy point. Nutanix is near an alternate handle entry. Investors can take advantage of new entries, but stay cool. Don't treat the past few weeks as a "new normal" for stock performance. Nvidia stock is on , with Astera Labs on the Leaderboard watchlist. Astera Labs stock and Nvidia are on the . Dow Jones Futures Today Dow Jones futures open at 6 p.m. ET on Sunday, along with S&P 500 futures and Nasdaq 100 futures. Remember that overnight action in and elsewhere doesn't necessarily translate into actual trading in the next regular session. Stock Market Rally The stock market rally had a strong performance that was even better than major indexes suggested, especially the Nasdaq. The Dow Jones Industrial Average gained nearly 2% in last week's . The S&P 500 index and Nasdaq composite gained 1.7%. The small-cap Russell 2000 surged 4.5%. All of these indexes tested their 21-day lines multiple times in the past week, moving off those levels. The Nasdaq, which hit resistance at the 19,000 level, is still relatively close to the 21-day. But it's also close to its postelection peaks. The Invesco S&P 500 Equal Weight ETF ( ) popped 2.55%, outperforming the S&P 500 and matching a record high Friday. The First Trust Nasdaq 100 Equal Weighted Index ETF ( ) bounced 3.5%, outperforming the Nasdaq 100 and the Nasdaq. Stalling megacaps are not just masking the underlying market strength, they may be helping to fuel the underlying strength. Big institutions selling relatively small slices of, say, Nvidia or Google might still be raising several billion dollars or more. That's massive firepower for bidding up much-smaller stocks. The 10-year Treasury yield fell two basis points to 4.41%, trading in a tight range near five-month highs. The two-year Treasury yield, more closely tied to the Fed rate outlook, climbed for a 10th straight week, up seven basis points to 4.37%. U.S. crude oil futures jumped 6.5% to $71.24 a barrel last week. Bitcoin surged 10.8% to $99,290.67, up nearly 49% over the past four weeks. ETFs Among growth ETFs, the Innovator IBD 50 ETF ( ) soared 9.2% last week to a two-year high. The iShares Expanded Tech-Software Sector ETF ( ) popped 4.9% to record levels. The VanEck Vectors Semiconductor ETF ( ) gained 1.95%, just below the 10-week line. Nvidia stock is the dominant holding in SMH. ARK Innovation ETF ( ) jumped 5.1% last week and ARK Genomics ETF ( ) rallied 5.2%. SPDR S&P Metals & Mining ETF ( ) ran up 5.5% last week. The Global X U.S. Infrastructure Development ETF ( ) advanced 3.6%. U.S. Global Jets ETF ( ) fell 1.1%. SPDR S&P Homebuilders ETF ( ) bounced 3.6%. The Energy Select SPDR ETF ( ) climbed 2.7% and the Health Care Select Sector SPDR Fund ( ) rebounded 1.6%. The Industrial Select Sector SPDR Fund ( ) notched a 2.5% gain. The Financial Select SPDR ETF ( ) rose 1.7%. Nvidia Stock Nvidia stock fell 3 cents to 141.95 for the week. Shares briefly spiked to a record 152.89 Thursday morning following earnings, but finished the week just below the 21-day moving average. NVDA stock held the 140.76 consolidation buy point, according to . But it's gone nowhere over the past month, and is essentially flat since the June peak. Late Wednesday, Nvidia reported a 103% EPS gain last quarter with revenue soaring 94%, both beating. But the AI chipmaker only guided slightly higher on the current quarter, which will include Blackwell AI chip shipments. ( ) is hitting resistance near an early entry, but ( ) and ( ) are clear laggards. Astera Labs: New AI Chip Leader Astera Labs is a minnow next to these chip giants, with $113.1 million in Q3 sales vs. Nvidia's $35.1 billion. But the 2024 IPO is the clear AI chip stock leader right now. The company is now profitable with huge revenue growth vs. a year earlier and quarter on quarter. Shares have nearly tripled from their early August low of 36.22. Last week, Astera Labs stock leapt 18.3% to 102.28. On Thursday, following Nvidia earnings, ALAB stock cleared a 100.06 high-handle entry on a consolidation that started in late March. Astera Labs is in range of that entry, though shares are extended 47% above their 50-day line. What To Do Now The stock market rally is looking strong, with the indexes near record highs and leaders powering higher. Some of the megacaps may be sitting out for a time. Google stock and ( ) are clear laggards right now, but ( ) and ( ) have faded off. Nvidia stock is in a buy zone, but it isn't going anywhere. So, investors need to adjust. Luckily, a slew of other stocks have been acting well from a variety of sources. Many stocks flashed buy signals last week, offering opportunities to add exposure. There are still stocks in buy zones or setting up. Investors, who should be heavily invested, can look for incremental buys or add-on purchases, while also paring laggards. But after the huge gains in many leaders over the past few weeks, keep a level head. Weekly gains of 10%, 20% in leading stocks aren't the new normal. Enjoy these periods, but buying extended and other super-aggressive moves that worked in the past few weeks could backfire now. Read every day to stay in sync with the market direction and leading stocks and sectors.
None
Abandoned mines in the US pose dangers to people and property when land gives way
Cloud Computing in Education Market Is Booming So Rapidly | Major Giants Google (Google Workspace), MicrosoftMatt Eberflus' dismissal from Bears came after 's--- show' postgame locker room speech: reportI like Martha Stewart. Always have. Two recent documentaries, "Martha" on Netflix and the CNN series "The Many Lives of Martha Stewart," follow the Greek drama that make Stewart a cultural fascination to this day. They recount the jihad against this visionary who came under attack for being a woman with fierce ambition. Admittedly, Stewart's hard edged perfectionism and nuclear-powered drive had created some tension with her product, the "soft" home arts of cooking, flower arranging and chair reupholstering. But did she have to be destroyed? Sure, Stewart engaged in some insider trading that may have seemed nothing more than an innocent stock tip. She shouldn't have lied about it to the FBI. But did journalist Dominick Dunne have to call her the "Goddess of Greed" over a transaction that saved the creator of a billion-dollar business only $45,673? It sure didn't merit five months in prison. In 1987, the cultural hyenas jumped on her for signing a $5 million contract with Kmart. Stewart was allegedly "selling out" the domestic lifestyle she had cultivated, moving away from authenticity toward mass production and profit. Heaven forfend. The year before, The Disney Co.'s CEO walked off with a $90 million severance check after 14 months of undistinguished performance. She was tenacious. So what? Male executives wore that badge proudly. This woman built a business empire based on creating artistic cheese trays and making wreaths from dry leaves. Try that, Elon Musk. Some of her trouble came in the sub-message that our home lives had turned slovenly because Americans had stopped caring about family dinners and dust balls under the sofa. Some translated that not as a call to do better but as an indictment. But Stewart had no army. Those who accused her of creating unrealistic expectations for women juggling work and family should have been asked: Whose expectations? One could simply enjoy watching her on TV or reading her magazine, Martha Stewart Living. Her projects were properly labeled "aspirational." I once tried to follow her instructions for coloring cloth with natural vegetable dyes. Two hours later, I ended up with blotchy fabric and hands stained by beet juice. I tried, I failed, and I had a funny story to tell. I was intrigued by her demonstration on how to roll an ironed tablecloth in parchment paper to prevent wrinkles. And how nice that she could whip up 80 perfectly iced little cakes in no time. I can't do a single backflip. Must I resent Simone Biles for executing a triple-double in one move? It took Superwoman strength to plant an orchard with 122 trees and who knows how many rose bushes. One interviewer noted that people living in Detroit or New York City couldn't do rose gardens. She responded, "But yes, they want roses." The fantasy was more than half the point. Women were among her leading inquisitors. One called her "the most intimidating homemaker on earth." Another female interviewer tells her, "Either they worship you or they say you make us crazy." There was a third possibility — that they found her entertaining. Stewart can lay claim to two heroic feats: She played a big part in improving the quality of American homelife. And she rebuilt a business that had been left for dead. Above all, Martha was a great tough broad. You saw how TV's Larry King kept badgering her about her failed marriage in a way that would have seemed bizarre had the executive been a man. "I had sacrificed a marriage because of the allure of a great job," she finally relented. And she didn't regret it? She did not. I like Stewart, still going strong at 83. More than ever. Harrop, who lives in New York City and Providence, Rhode Island, writes for Creators Syndicate: fharrop@gmail.com . Be the first to know Get local news delivered to your inbox!
NoneNASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD, Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark "SecondReadAI" by Lunit, Inc. The corrected release follows: iCAD, Inc . ICAD ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions. iCAD and Cascaid Health Partner to Expand Access to AI-Driven Breast Health In alignment with their vision to enable all women to access to AI-powered breast health services, iCAD and Cascaid Health will unveil their collaboration to integrate the ProFound AI Breast Health Suite into Cascaid's leading edge digital health marketplace and access to care platform. Scheduled for beta launch in Q1 2025, this partnership between iCAD and Cascaid Health will launch ProFound Health, a virtual care model powered by Cascaid. ProFound Health will enable women who have not otherwise received an AI-read on their screening mammogram to access iCAD's advanced breast health technology. The initiative reflects both companies' dedication to democratizing access to life-saving technology and creating a world where cancer can't hide. ProFound Health partnership will offer virtual second reads of mammograms leveraging ProFound AI Breast Health Suite, an AI service providing patients without access to AI an opportunity to receive enhanced breast health insights. The initial service will include a second read detection, breast density assessment, and cancer risk evaluation from a Cascaid-affiliated specialist network of clinical experts in women's health through Cascaid's seamlessly integrated digital platform. By combining AI insights with expert clinical reviews, ProFound Health ensures that patients everywhere, regardless of location, can receive precision screening and personalized care. "ProFound Health empowers patients with access to critical information about their mammograms and overall breast health, allowing them to make informed decisions and take control of their care journey," said Dana Brown, CEO and President of iCAD. "Our collaboration with Cascaid Health's network of clinicians and AI-powered solutions is part of our ongoing commitment to bridging gaps in breast cancer care, ensuring all patients everywhere can access the accuracy and timeliness of AI solutions, and ultimately transforming patient outcomes." "We believe that every woman should have access to the best possible information about her breast health and a high quality, personalized care plan to catch cancer early or prevent it altogether. Through our partnership with iCAD, we're addressing a critical need to improve access to advanced breast health services," said Dr. Candace Westgate, Director of Women's Health for Cascaid Health. "ProFound Health is more than just a technological innovation, it's a lifeline that empowers patients and healthcare providers with actionable insights, bridging care gaps and ensuring equitable access to precision screening and personalized breast cancer care." Advancing Next Generation AI Breast Health Solutions at RSNA 2024 In addition to ProFound Health, iCAD will feature its flagship ProFound Detection Version 4.0, which recently received FDA clearance. This next-generation AI solution enhances breast cancer detection by incorporating prior exams into current analysis, improving the detection of aggressive cancers by 22%, reducing cases with no marks by 18%, and providing clinicians with more reliable insights for better decision-making. "Every two minutes, someone loses their life to breast cancer—a disease affecting over 2.3 million women annually. Early detection is critical, as five-year survival rates exceed 99% for stage 1 disease. Yet traditional mammography misses over 20% of breast cancers, particularly in dense tissue, resulting in potentially avoidable late-stage diagnoses," said Dana Brown, President and CEO of iCAD, Inc. "ProFound Detection Version 4 revolutionizes breast cancer detection by uniquely integrating prior exams into its analysis. This advanced capability enhances sensitivity, sharpens precision, and provides radiologists with a deeper, longitudinal view of a patient's breast health. By enabling earlier and more accurate detection, especially in dense tissue, ProFound Detection Version 4 sets a new standard in breast health AI, empowering providers to improve outcomes and save lives. Together with our strategic partnerships, we are advancing the fight against cancer and making a meaningful difference for patients worldwide." ICAD'S RSNA 2024 Program Highlights AI-Powered Insights: Advancing Cancer Detection Oral Abstract Presentation : "Real World Effect of Artificial Intelligence on Histopathology and Stage in Breast Cancer Screening" Presenter : Kathy Schilling, M.D., Boca Raton Regional Hospital When : Sunday, December 1 | 10:30–11:30 AM Where : S406A: S2-SSBR01-6 Details : Dr. Kathy Schilling discusses the experience with tenured radiologists on how the current use of ProFound AI improves cancer detection, even in women with dense breast tissue, compared to their performance prior to the implementation of AI. In addition, she will describe the decrease in the mean size and stage of cancers after the implementation, along with an increase in the diagnosis of lobular cancers. "The integration of ProFound AI alongside our nine dedicated breast radiologists has demonstrated remarkable improvements in cancer detection and patient outcomes across our imaging network," said Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital. "We've seen a 23% overall increase in cancer detection rates, a 4% rise in invasive cancer detection, and doubled rates of lobular cancer detection. ProFound AI also enhanced detection in dense breast tissue by 32%, reduced invasive cancer size by 12%, and lowered histopathologic stage with a 40% reduction in T2 tumors—all without increasing DCIS diagnoses or recall rates. These advancements underscore the transformative potential of AI in improving early breast cancer detection, elevating patient care, and ultimately saving lives." AI Theater Presentation : "The Thin White Line: Which Calcifications Matter? Advances in AI Breast Cancer Detection" Presenter : Chirag R. Parghi, M.D., M.B.A., Solis Mammography When : Tuesday, December 3 | 1:00–1:20 PM Where : AI Showcase Theater (South Hall A), Booth 5536 Details : A look at how ProFound Detection's next-generation capabilities reduce uncertainty in interpreting calcifications on a mammogram by displaying 20% fewer marks related to vascular calcifications and 51% fewer marks related to non-vascular calcifications, leading to enhanced precision and accuracy. Collaborative Panels and Partner Showcases GE HealthCare Expert Corner : Seamless integration of ProFound AI with GE mammography systems to enhance workflow and detection capabilities. Daily at Booth 7330 (North Hall). Densitas Panel : "Elevating Patient Care through Quality Images & Precise Detection." Daily at Booth 4747 (South Hall). CancerIQ : Daily at Booth 4747(South Hall). Blackford Panel : "Enhancing Breast Cancer Care with AI." Tuesday, December 3, 2:30-2:50 PM at Booth 4729 (South Hall). CARPL.ai Breast AI Panel : Wednesday, December 4, 11:00 AM at Booth 5733 (South Hall). Customer Appreciation Event iCAD will be hosting a customer appreciation event, "AI in the Sky: Discover ProFound Insights & Breast Health Innovations," on Sunday, December 1, at 6:00 PM at VU Rooftop in Chicago. Network with industry experts, hear insights from key opinion leaders including iCAD's CEO and Board of Directors, and explore how iCAD's solutions are transforming breast health. Visit the iCAD RSNA 2024 event page for the latest updates, event details, and partnership announcements. About Cascaid Health Cascaid Health Inc. delivers a personalized, expert-driven proactive and preventative approach, supported by an integrated platform designed to promote longevity, detect issues early, reverse risks, and optimize healthspan for all. The company's platform offers a curated marketplace featuring innovative products, services, and access to world-class multidisciplinary experts in women's health, precision health, lifestyle medicine, wellness, and performance. Cascaid Health Inc. is committed to advancing health equity, ensuring that cutting-edge healthcare solutions are accessible to everyone. About iCAD, Inc. iCAD, Inc. ICAD is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com . Forward-Looking Statements Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC's website at http://www.sec.gov . CONTACTS Media Inquiries: pr@icadmed.com Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations icad@imsinvestorrelations.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.President-elect Donald Trump has nominated Jared Isaacman, a notable SpaceX customer, as head of NASA. You may remember Isaacman as the billionaire who made the first private spacewalk last September as part of the SpaceX Polaris Dawn mission. That said, he's a professional flier and holds the speed record for the fastest in-atmosphere trip around the planet. It seems great news for SpaceX, which supplies NASA with rockets and capsules and is run by Elon Musk – the oligarch currently buddies with Trump and happily offering advice on how the US government should be run. "I am delighted to nominate Jared Isaacman, an accomplished business leader, philanthropist, pilot, and astronaut, as Administrator of the National Aeronautics and Space Administration," Trump said on his personal social network. "Jared will drive NASA’s mission of discovery and inspiration, paving the way for groundbreaking achievements in Space science, technology, and exploration." Isaacman made his fortune as the founder and CEO of payment processor Shift4, which he established at the tender age of 16. He later founded Draken International, which uses tactical jets to provide adversary air training for military pilots. He does have space experience, having purchased four tickets for an orbital trip in SpaceX's Dragon capsule back in 2022, then raffling off three of them. Wearing a SpaceX-designed lightweight spacesuit, Isaacman was the first person to take a brief step outside the capsule. The flight was one of three planned with SpaceX as part of Isaacman's Polaris Program to advance getting humans into space using Musk's rockets. Isaacman before his last SpaceX mission. Click to enlarge "On my last mission to space, my crew and I traveled farther from Earth than anyone in over half a century. I can confidently say this second space age has only just begun," Isaacman said in a post on X, better known as Twitter. "Space holds unparalleled potential for breakthroughs in manufacturing, biotechnology, mining, and perhaps even pathways to new sources of energy. There will inevitably be a thriving space economy—one that will create opportunities for countless people to live and work in space. With the support of President Trump, I can promise you this: We will never again lose our ability to journey to the stars and never settle for second place. Americans will walk on the Moon and Mars and in doing so, we will make life better here on Earth." With Musk apparently going to be co-head of the proposed US Department of Government Efficiency (DOGE), he'll have the whip hand on discretionary spending by Uncle Sam, which includes NASA's $24 billion budget. It's widely expected the ax will come down hard on a lot of the space agency's programs and work will be given to private contractors instead, and having a SpaceX-friendly boss of the agency would as we said be a big help for Elon, already the world's richest man. First on the chopping block is likely to be NASA's Space Launch System, which may not be a bad idea, actually. Its monstrously expensive throwaway rockets are outdated, though it may not be as easy to cancel as some might think. NASA has subcontracted the manufacturing to a lot of congressional districts and politicians may not be too keen on their constituents being out of work. Isaacman has at least made it into orbit and is clearly a huge space nerd. Whether or not that will cross over into being an effective administrator, however, is very much up in the air. ®